CN111377854A - Cxcr4抑制剂及其应用 - Google Patents
Cxcr4抑制剂及其应用 Download PDFInfo
- Publication number
- CN111377854A CN111377854A CN201911380346.8A CN201911380346A CN111377854A CN 111377854 A CN111377854 A CN 111377854A CN 201911380346 A CN201911380346 A CN 201911380346A CN 111377854 A CN111377854 A CN 111377854A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- radical
- group
- amino
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 title claims abstract description 24
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 title claims abstract description 24
- 239000003112 inhibitor Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims abstract description 18
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims abstract description 18
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 16
- 230000001483 mobilizing effect Effects 0.000 claims abstract description 14
- 230000003993 interaction Effects 0.000 claims abstract description 11
- -1 hydroxy, amino, sulfonyl Chemical group 0.000 claims description 110
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000004122 cyclic group Chemical group 0.000 claims description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 210000001185 bone marrow Anatomy 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 208000032839 leukemia Diseases 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 16
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 14
- 239000000651 prodrug Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 12
- 210000005259 peripheral blood Anatomy 0.000 claims description 12
- 239000011886 peripheral blood Substances 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 239000000460 chlorine Chemical group 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 239000011737 fluorine Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 208000030507 AIDS Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 8
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 7
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 7
- 229960000684 cytarabine Drugs 0.000 claims description 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 4
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 4
- 108010032976 Enfuvirtide Proteins 0.000 claims description 4
- FNELVJVBIYMIMC-UHFFFAOYSA-N Ethiprole Chemical compound N1=C(C#N)C(S(=O)CC)=C(N)N1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl FNELVJVBIYMIMC-UHFFFAOYSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 4
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 4
- 229960004748 abacavir Drugs 0.000 claims description 4
- 229960000548 alemtuzumab Drugs 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960002448 dasatinib Drugs 0.000 claims description 4
- 229960005319 delavirdine Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 4
- 229960003804 efavirenz Drugs 0.000 claims description 4
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims description 4
- 229960002062 enfuvirtide Drugs 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 229940080856 gleevec Drugs 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- 229960001627 lamivudine Drugs 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 229960000689 nevirapine Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 229960001203 stavudine Drugs 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 4
- 229960001796 sunitinib Drugs 0.000 claims description 4
- 229940120982 tarceva Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960004556 tenofovir Drugs 0.000 claims description 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 229960000523 zalcitabine Drugs 0.000 claims description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 4
- 229960002555 zidovudine Drugs 0.000 claims description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000027219 Deficiency disease Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 229950009760 epratuzumab Drugs 0.000 claims description 2
- 125000003106 haloaryl group Chemical group 0.000 claims description 2
- 125000005216 haloheteroaryl group Chemical group 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 229940037201 oris Drugs 0.000 claims description 2
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 230000028709 inflammatory response Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 103
- 238000006243 chemical reaction Methods 0.000 description 79
- 150000003254 radicals Chemical class 0.000 description 55
- 239000000543 intermediate Substances 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
- 230000015572 biosynthetic process Effects 0.000 description 39
- 238000003786 synthesis reaction Methods 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- 239000012074 organic phase Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- 239000002994 raw material Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 238000001035 drying Methods 0.000 description 18
- 125000002619 bicyclic group Chemical group 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003419 tautomerization reaction Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 4
- 229960002169 plerixafor Drugs 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 3
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 3
- 208000012124 AIDS-related disease Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UPPPRUGHDBCPEF-UHFFFAOYSA-N Nic 17 Natural products CC(C(O)CC(=O)C)c1ccc2C3C4OC4C5(O)CC=CC(=O)C5(C)C3CCc2c1 UPPPRUGHDBCPEF-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000000994 L-ascorbates Chemical class 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 150000004701 malic acid derivatives Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- ITZPOSYADVYECJ-UHFFFAOYSA-N n'-cyclohexylpropane-1,3-diamine Chemical compound NCCCNC1CCCCC1 ITZPOSYADVYECJ-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 1
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 1
- XYPVBKDHERGKJG-UHFFFAOYSA-N 4-(bromomethyl)benzaldehyde Chemical compound BrCC1=CC=C(C=O)C=C1 XYPVBKDHERGKJG-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical group [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AYESKMWPTSCYSJ-UHFFFAOYSA-N bis(hydroxymethyl)phosphanylmethanol;hydrochloride Chemical compound [Cl-].OC[PH+](CO)CO AYESKMWPTSCYSJ-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical class CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005992 dihydrobenzisothiazinyl group Chemical group 0.000 description 1
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005612 glucoheptonate group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 208000003669 immune deficiency disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical group OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000003521 protein stability assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- DVECLMOWYVDJRM-UHFFFAOYSA-N pyridine-3-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=CN=C1 DVECLMOWYVDJRM-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
本发明涉及化合物及其在制备药物中的用途、含有该化合物的药物组合物、药物载体及药物联用。所述化合物为如式(I)所示的化合物、其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药。本发明化合物对CXCR4‑SDF‑1α轴显示出很强的抑制活性,在体内稳定性好,具有良好的吸收效果以及较高的生物利用度,可以有效地干扰或阻断SDF‑1α与CXCR4的相互作用,起到动员造血干细胞、治疗肿瘤疾病、炎症反应、自身免疫性疾病等效果,具有较好的应用前景。
Description
技术领域
本发明涉及医药领域。具体地,本发明涉及CXCR4抑制剂及其应用。更具体地,本发明涉及化合物、化合物在制备药物中的用途、药物组合物、药物载体、药物联用、筛选药物和筛选目标物的方法。
背景技术
CXC趋化因子受体4(CXCR4)和基质细胞衍生因子1(SDF-1)分别属于趋化因子CXC亚家族和趋化因子受体G蛋白偶联受体超家族。CXCR4是一种重要的趋化因子受体,广泛表达于多种造血细胞(中性粒细胞、单核和巨噬细胞、T、B淋巴细胞)、血液和骨髓中的造血干细胞、内皮前体细胞、血液来源的树突状细胞和朗格汉斯细胞中。同时,也高表达于血管内皮细胞、中心和周围神经系统的神经元和神经干细胞及小胶质和星形胶质细胞中。CXCR4是SDF-1α的特异性受体,两者构成CXCR4-SDF-1α生物轴,通过激活细胞内多种信号传导通路,调节细胞的增殖和迁移能力。
大量研究发现CXCR4-SDF-1α轴在调节人体的免疫系统、循环系统和神经系统中发挥重要作用,而且它们的相互作用及其介导的信号传导与病毒感染、肿瘤发生发展和转移、炎症和自身免疫性疾病等多种疾病密切相关。利用CXCR4抑制剂干扰或阻断SDF-1α与CXCR4的相互作用,起到如下作用:1)可动员骨髓中的造血干细胞到外周血,便于采集造血干细胞,用于多发性骨髓瘤和非霍杰金淋巴瘤的治疗;2)可阻断HIV-1入侵T细胞,从而抑制艾滋病的疾病进展;3)可以为抗肿瘤转移提供新的治疗手段;4)可以通过破坏骨髓微环境的保护、抑制白血病细胞向骨髓内外迁移浸润、动员白血病细胞到外周血中并提高其对化疗药物的敏感性,用于白血病的治疗;5)可与肿瘤免疫治疗药物或疗法联合使用治疗肿瘤;6)可治疗免疫缺陷疾病,如WHIM综合征等。
目前对于干细胞动员、HIV感染、血液肿瘤、实体肿瘤和免疫缺陷疾病的药物有很大的需求,而已上市药物较少,且无法满足患者的需求。因此,高活性的CXCR4抑制剂亟待开发,为上述疾病患者提供更好的治疗。
发明内容
本发明旨在至少在一定程度上解决现有技术中存在的技术问题至少之一。
在本发明的一个方面,本发明提出了一种化合物。根据本发明的实施例,所述化合物为如式(I)所示的化合物、其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药:
L选自C2~10烯基、C2~10炔基、C3~8环烷基、C3~6杂环基、芳基、C1~5杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基或者C1~12螺杂环基,或者L、及与相连的N及R2形成环状结构;
R1选自键、氢、磺酰基、亚磺酰基、C1~6烷基磺酰基、氨基C1~6烷基、C1~6烷基亚磺酰基、羰基、C1~6烷基羰基、氨基酸、酰胺键、 或者其中A、B、C、D、E、F、G各自独立地为C、N、O、S原子,或者中的C、N及R7形成环状结构,或者R1与R2以及连接的同一N原子形成环状结构;或者R2、N、和L形成环状结构;
R2、R3和R4各自独立地选自氢、羟基、氨基、磺酰基、亚磺酰基、羰基、C1~6烷基、C2~10烯基、C2~10炔基、C1~6烷氧基、氨基C1~6烷基、C1~6烷基磷酰基、C1~6烷基羰基、C3~8环烷基、C3~8杂环基、芳基、C1~10杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基或者C1~12螺杂环基;或者R3、R4、及与两端相连的N原子之间形成环;
R5和R6各自独立地选自氢、磺酰基、亚磺酰基、羰基、氨基、C1~10烷基、C2~10烯基、C2~10炔基、C1~6烷氧基、氨基C1~6烷基、C1~6烷基磷酰基、C1~6烷基羰基、C1~6烷基芳基、C3~8环烷基、C3~8杂环基、C1~4烷基C3~8杂环基、芳基、C1~10杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基或者C1~12螺杂环基;
R7选自氢、氨基、磺酰基、亚磺酰基、羰基、C1~6烷基、C2~10烯基、C2~10炔基、C1~6烷氧基、氨基C1~6烷基、C1~6烷基磷酰基、C1~6烷基羰基、C1~6烷基芳基、C3~8环烷基、C3~8杂环基、芳基、C1~10杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基、C1~12螺杂环基;
其中,
所述烯基、炔基、烷氧基、氨基、烷基、氨基烷基、环烷基、烷基磷酰基、杂环基、芳基、杂芳基、烷基羰基、烷基杂环基、烷基芳基、稠合环基、稠合杂环基、螺环基、螺杂环基、磺酰基和亚磺酰基可分别独立地被一个或者多个烷基、烯基、炔基、氟、氯、溴、碘、卤代烷基、卤代芳基、卤代杂芳基、羟基、氨基、羰基、羧基、胍基、脒基、磺酰基、亚磺酰基、烷氧基、氨基烷基、烷基磷酰基、烷基羰基、环烷基、杂环基、芳基、杂芳基、稠合环基、稠合杂环基、螺环基、螺杂环基所取代;
n1、n2和n3各自独立地为0~10的整数。
本发明化合物对CXCR4-SDF-1α轴显示出很强的抑制活性,在动物体内的药代动力学试验中显示出良好的吸收、较高的生物活性和利用度,低毒,尤其是在体内具有较强的稳定性,不易分解,药效时间长,可以有效地干扰或阻断SDF-1α与CXCR4的相互作用,既可以有效地动员造血干细胞,为多种血液肿瘤提供新的治疗手段,也可以通过破坏骨髓微环境的保护、抑制白血病细胞向骨髓内外迁移浸润、动员白血病细胞到外周血中并提高其对化疗药物的敏感性,起到治疗白血病的效果,同时,CXCR4-SDF-1α在实体瘤、艾滋病、自身免疫疾病和炎性类疾病也有很重要的生理和病理作用,可作为以上疾病的靶点或辅助治疗的手段,具有很好的应用前景。
根据本发明的实施例,上述化合物还可以具有下列附加技术特征:
R2选自氢、C1~6烷基、C3~6环烷基、C3~6杂环基、氨基C1~4烷基或C1~5杂芳基,所述烷基、环烷基、杂环基、氨基烷基或杂芳基可任选的被一个或多个H、C1~4烷基、氟、氯、溴、碘、氨基或C1~5杂芳基所取代;
R5选自C1~6烷基、芳基、C3~6环烷基、C3~6杂环基或C1~5杂芳基,其中,所述烷基、环烷基、杂环基、芳基或杂芳基可任选地被一个或多个氟、氯、溴、碘、C1~6烷基、C1~6环烷基、芳基、C1~5杂芳基或C1~6杂环基取代;
R6选自C1~4烷基、氨基、磺酰基、亚磺酰基、羰基、氨基C1~6烷基、C1~6烷基芳基、C1~4烷基C3~8杂芳环基、C3~6环烷基或C3~6杂环基,其中,所述烷基、氨基、羰基、磺酰基、亚磺酰基、氨基烷基、烷基芳基、烷基杂环基、环烷基或杂环基可任选地被一个或多个氢、氟、氯、溴、碘、氨基、芳基、C1~5杂芳基、卤代C1~5杂芳基、C2~6杂环基或C1~4烷基磷酰基取代;
R7选自C1~6烷基、芳基、C1~6烷基芳基、C1~5杂芳基、C1~6烯基、C3~6环烷基、C3~6杂环基、磺酰基或亚磺酰基,所述烷基、芳基、杂芳基、烷基芳基、烯基、环烷基或杂环基可任选地被一个或多个氢、氟、氯、溴、碘、C1~6烷基、C3~6环烷基、芳基、C1~5杂芳基、脒基、胍基或氨基所取代;
L选自芳基、C1~5杂芳基、C2~4炔基、C3~6环烷基、C3~6杂环基、C6~12稠合环基或C1~12稠合杂环基,所述芳基、杂芳基、炔基、环烷基、稠合环基或稠合杂环基可任选地被一个或多个氢、氟、氯、溴、碘、C1~6烷基、C3~6环烷基、C3~6杂环基、氨基、羟基、羧基、芳基、C1~5杂芳基、卤代C1~6烷基、C1~6烷氧基、C1~6氨基烷基或所取代。
根据本发明的实施例,L选自以下之一的结构: 或者L可任选地被一个或多个氢、氟、氯、溴、碘、C1~10烷基、C3~8环烷基、C3~8杂环基、氨基、羟基、羧基、芳基、C1~5杂芳基、卤代C1~6烷基、C1~6烷氧基、C1~6氨基烷基或所取代,其中A、B、C、D、E、F、G、H和I各自独立地为H、C、N、O、S原子。
其中A、B、C、D、E、F、G、H和I各自独立地为H、C、N、O、S原子;
R8、R9或R10各自独立地为氢、氟、氯、溴、碘、C1~4烷基、氨基C1~4烷基或C1~4烷氧基。
所述稠合环基被一个或多个H、C1~3烷基、氟、氯、溴、碘或C1~3烷氧基所取代。
(1)所述芳基上碳原子被非氢基的取代基所取代;
(4)R5为环烷基,所述环烷基被一个或多个氟、氯、溴、碘、羟基、氨基、芳基、C1~4烷基、C1~8环烷基或C1~8杂环基所取代;
(5)R6为羰基、磺酰基、亚磺酰基、氨基或氨基C1~4烷基,所述羰基、磺酰基、亚磺酰基、氨基或氨基C1~4烷基可任选地被一个或多个氢、氟、氯、溴、碘、氨基、芳基、C1~5杂芳基、卤代C1~5杂芳基、C2~6杂环基或C1~4烷基磷酰基取代;
(6)R7为C1~4烷基、C1~4烯基、C1~5杂芳基或C3~6环烷基,其中,所述烷基不可被烷基、脒基、氨基、C1~5杂芳基所取代。
根据本发明的实施例,所述化合物为下列所示之一的化合物、其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药:
根据本发明的实施例,所述药学上可接受的盐,包括选自三氟乙酸盐、盐酸盐、醋酸盐、磷酸盐、氢溴酸盐、乳酸盐、双羟基茶酸盐、硫酸盐、甲磺酸盐、甲苯磺酸盐、柠檬酸盐、酒石酸盐、富马酸盐、马来酸盐和苹果酸盐的至少之一。
在本发明的又一方面,本发明提出了前面所述化合物在制备药物中的用途。根据本发明的实施例,所述药物用于治疗肿瘤疾病、艾滋病、骨髓移植、镰状细胞性贫血、造血干细胞移植、创伤、心肌梗死、嗜中性白血球减少症、缺血性疾病、神经性疾病、视网膜静脉阻塞、呼吸系统性疾病、肠胃疾病、皮肤疾病、炎症反应或免疫缺陷疾病。本发明化合物显示出对CXCR4-SDF-1α轴有很强的抑制活性,在动物体内的药代动力学试验中显示出良好的吸收、较高的生物活性和利用度,低毒,尤其是在体内具有较强的稳定性,药效时间长,可以有效地干扰或阻断SDF-1α与CXCR4的相互作用,既可以有效地动员造血干细胞,为多种血液肿瘤提供新的治疗手段,也可以通过破坏骨髓微环境的保护、抑制白血病细胞向骨髓内外迁移浸润、动员白血病细胞到外周血中并提高其对化疗药物的敏感性,起到治疗白血病的效果,同时,CXCR4-SDF-1α在实体瘤、艾滋病、自身免疫疾病和炎性类疾病也有很重要的生理和病理作用,可作为以上疾病的靶点或辅助治疗的手段,具有很好的应用前景。
根据本发明的实施例,所述药物抑制CXCR4的表达或者阻断CXCR4和SDF-1α之间的相互作用。本发明的化合物可以通过竞争性地与CXCR4拮抗性结合从而阻断CXCR4和天然配体SDF-1α之间的相互作用。
根据本发明的实施例,所述药物用于动员骨髓中的造血干细胞以用于自体或异体造血干细胞移植,用于多发性骨髓瘤和非霍杰金淋巴瘤疾病的治疗。
根据本发明的实施例,所述药物用于动员骨髓中的干细胞,用于白血病的治疗。
根据本发明的实施例,所述药物用于动员骨髓中的急性髓细胞白血病的癌细胞到外周血,用于白血病的治疗。
根据本发明的实施例,所述药物抑制肿瘤细胞转移,用于肿瘤的治疗。
根据本发明的实施例,所述药物抑制HIV-1入侵T细胞,用于艾滋病的治疗。
根据本发明的实施例,所述药物用于自身免疫缺陷疾病的治疗。
根据本发明的实施例,所述药物在制备造血干细胞/祖细胞动员剂和/或在过表达CXCR4的肿瘤组织中作为检测肿瘤标志物的应用。
本发明的又一方面,本发明提出了一种药物组合物。根据本发明的实施例,所述药物组合物包括前面所述化合物。本发明化合物显示出对CXCR4-SDF-1α轴有很强的抑制活性,在动物的体外体内的药代和药效实验中表现出较好的成药性,尤其是在体内具有较强的稳定性,药效时间长可以有效地干扰或阻断SDF-1α与CXCR4的相互作用,既可以为血液肿瘤提供新的治疗手段,也可以通过破坏骨髓微环境的保护、抑制白血病细胞向骨髓内外迁移浸润、动员白血病细胞到外周血中并提高其对化疗药物的敏感性,起到治疗肿瘤疾病、免疫缺陷性疾病、艾滋病和炎性反应等效果,具有较好的应用前景。
根据本发明的实施例,所述药物组合物进一步包括药学上可接受的辅料、载体、赋形剂、溶媒或它们的组合。根据本发明的实施例,所述药物组合物进一步包含治疗剂,所述治疗剂选自下列的至少之一:马拉韦罗、恩夫韦肽、齐多夫定、扎西他宾、司他夫定、拉米夫定、萘韦拉平、地拉韦定、阿巴卡韦、依非韦伦、替诺福韦、乙曲西他槟、依曲韦润、利匹韦润、顺铂、环磷酰胺、阿糖胞苷、5-氟尿嘧啶、吉西他滨、紫杉醇、多西他赛、阿霉素、格列卫、特罗凯、索拉菲尼、达沙替尼、拉帕替尼、舒尼替尼、埃罗替尼、吉非替尼、Tisagenlecleucel、益基利仑赛、阿仑单抗、阿特珠单抗、阿维单抗、伊匹单抗、奥法木单抗、纳武利尤单抗、帕博利珠单抗、利妥昔单抗、度伐鲁单抗、卡瑞利珠单抗、特伦普利单抗、信迪利单抗、替雷利珠单抗、阿替利珠单抗、西妥昔单抗和曲妥珠单抗的赫赛汀。
在本发明的又一方面,本发明提出了一种药物载体。根据本发明的实施例,所述药物载体包括前面所述化合物。本发明化合物对CXCR4-SDF-1α轴显示出很强的抑制活性,在动物体内的药代动力学试验中吸收、分布、代谢和排泄(ADME)均表现出良好的成药性数据,显示出良好的吸收、较高的生物活性和利用度,低毒,尤其是在体内具有较强的稳定性,药效时间长,可以有效地干扰或阻断SDF-1α与CXCR4的相互作用,既可以为血液肿瘤提供新的治疗手段,也可以通过动员白血病细胞到外周血中并提高其对化疗药物的敏感性,起到治疗肿瘤疾病、免疫缺陷性疾病、艾滋病和炎性反应等效果,具有较好的应用前景。
在本发明的又一方面,本发明提出了一种药物联合。根据本发明的实施例,所述药物联合包含:前面所述化合物或药物组合物;以及一种或多种用于治疗肿瘤疾病、艾滋病、炎症反应以及免疫缺陷疾病的药物。本发明化合物对CXCR4-SDF-1α轴显示出很强的抑制活性,在动物体内的药代动力学试验中显示出良好的吸收、较高的生物活性和利用度,低毒,尤其是在体内具有较强的稳定性,药效时间长,可以有效地干扰或阻断SDF-1α与CXCR4的相互作用,既可以为血液肿瘤提供新的治疗手段,也可以通过破坏骨髓微环境的保护、抑制白血病细胞向骨髓内外迁移浸润、动员白血病细胞到外周血中并提高其对化疗药物的敏感性,起到治疗肿瘤疾病、免疫缺陷性疾病、艾滋病和炎性反应等效果,具有较好的应用前景。
根据本发明的实施例,所述药物选自下列的至少之一:马拉韦罗、恩夫韦肽、齐多夫定、扎西他宾、司他夫定、拉米夫定、萘韦拉平、地拉韦定、阿巴卡韦、依非韦伦、替诺福韦、乙曲西他槟、依曲韦润、利匹韦润、顺铂、环磷酰胺、阿糖胞苷、5-氟尿嘧啶、吉西他滨、紫杉醇、多西他赛、阿霉素、格列卫、特罗凯、索拉菲尼、达沙替尼、拉帕替尼、舒尼替尼、埃罗替尼、吉非替尼、Tisagenlecleucel、益基利仑赛、阿仑单抗、阿特珠单抗、阿维单抗、伊匹单抗、奥法木单抗、纳武利尤单抗、帕博利珠单抗、利妥昔单抗、度伐鲁单抗、卡瑞利珠单抗、特伦普利单抗、信迪利单抗、替雷利珠单抗、阿替利珠单抗、西妥昔单抗或曲妥珠单抗的赫赛汀。
本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。
附图说明
本发明的上述和/或附加的方面和优点从结合下面附图对实施例的描述中将变得明显和容易理解,其中:
图1显示了根据本发明一个实施例的NIC108动员AML模型小鼠的肿瘤细胞并协同提升化疗药物阿糖胞苷的效果示意图;
图2显示了根据本发明一个实施例的动员出的造血干细胞所形成集落的数量分析示意图。
具体实施方式
现在详细描述本发明的某些实施方案,其实例由随附的结构式和化学式说明。本发明意图涵盖所有的替代、修改和等同技术方案,它们均包括在如权利要求定义的本发明范围内。本领域技术人员应认识到,许多与本文所述类似或等同的方法和材料能够用于实践本发明。本发明绝不限于本文所述的方法和材料。在所结合的文献、专利和类似材料的一篇或多篇与本申请不同或相矛盾的情况下(包括但不限于所定义的术语、术语应用、所描述的技术,等等),以本申请为准。
应进一步认识到,本发明的某些特征,为清楚可见,在多个独立的实施方案中进行了描述,但也可以在单个实施例中以组合形式提供。反之,本发明的各种特征,为简洁起见,在单个实施方案中进行了描述,但也可以单独或以任意适合的子组合提供。
除非另外说明,本发明所使用的所有科技术语具有与本发明所属领域技术人员的通常理解相同的含义。本发明涉及的所有专利和公开出版物通过引用方式整体并入本发明。
定义或一般术语
术语“包含”为开放式表达,即包括本发明所指明的内容,但并不排除其他方面的内容。
“立体异构体”是指具有相同化学构造,但原子或基团在空间上排列方式不同的化合物。立体异构体包括对映异构体、非对映异构体、构象异构体(旋转异构体)、几何异构体(顺/反)异构体、阻转异构体,等等。
“手性”是具有与其镜像不能重叠性质的分子;而“非手性”是指与其镜像可以重叠的分子。
“对映异构体”是指一个化合物的两个不能重叠但互成镜像关系的异构体。
“非对映异构体”是指有两个或多个手性中心并且其分子不互为镜像的立体异构体。非对映异构体具有不同的物理性质,如熔点、沸点、光谱性质和反应性。非对映异构体混合物可通过高分辨分析操作如电泳和色谱,例如HPLC来分离。
本发明所使用的立体化学定义和规则一般遵循S.P.Parker,Ed.,McGraw-HillDictionary of Chemical Terms(1984)McGraw-Hill Book Company,New York;andEliel,E.and Wilen,S.,“Stereochemistry of Organic Compounds”,John Wiley&Sons,Inc.,New York,1994。
许多有机化合物以光学活性形式存在,即它们具有使平面偏振光的平面发生旋转的能力。在描述光学活性化合物时,使用前缀D和L或R和S来表示分子关于其一个或多个手性中心的绝对构型。前缀d和l或(+)和(-)是用于指定化合物所致平面偏振光旋转的符号,其中(-)或l表示化合物是左旋的。前缀为(+)或d的化合物是右旋的。一种具体的立体异构体是对映异构体,这种异构体的混合物称作对映异构体混合物。对映异构体的50:50混合物称为外消旋混合物或外消旋体,当在化学反应或过程中没有立体选择性或立体特异性时,可出现这种情况。
本发明公开化合物的任何不对称原子(例如,碳等)都可以以外消旋或对映体富集的形式存在,例如(R)-、(S)-或(R,S)-构型形式存在。在某些实施方案中,各不对称原子在(R)-或(S)-构型方面具有至少50%对映体过量,至少60%对映体过量,至少70%对映体过量,至少80%对映体过量,至少90%对映体过量,至少95%对映体过量,或至少99%对映体过量。
依据起始物料和方法的选择,本发明化合物可以以可能的异构体中的一个或它们的混合物,例如外消旋体和非对应异构体混合物(这取决于不对称碳原子的数量)的形式存在。光学活性的(R)-或(S)-异构体可使用手性合成子或手性试剂制备,或使用常规技术拆分。如果化合物含有一个双键,取代基可能为E或Z构型;如果化合物中含有二取代的环烷基,环烷基的取代基可能有顺式或反式构型。
所得的任何立体异构体的混合物可以依据组分物理化学性质上的差异被分离成纯的或基本纯的几何异构体,对映异构体,非对映异构体,例如,通过色谱法和/或分步结晶法。
可以用已知的方法将任何所得终产物或中间体的外消旋体通过本领域技术人员熟悉的方法拆分成光学对映体,如,通过对获得的其非对映异构的盐进行分离。外消旋的产物也可以通过手性色谱来分离,如,使用手性吸附剂的高效液相色谱(HPLC)。特别地,对映异构体可以通过不对称合成制备,例如,可参考Jacques,et al.,Enantiomers,Racematesand Resolutions(Wiley Interscience,New York,1981);PrinciplesofAsymmetricSynthesis(2nd Ed.Robert E.Gawley,JeffreyAubé,Elsevier,Oxford,UK,2012);Eliel,E.L.Stereochemistry of Carbon Compounds(McGraw-Hill,NY,1962);Wilen,S.H.Tables of Resolving Agents and Optical Resolutions p.268(E.L.Eliel,Ed.,Univ.of Notre Dame Press,Notre Dame,IN 1972);Chiral SeparationTechniques:A Practical Approach(Subramanian,G.Ed.,Wiley-VCH Verlag GmbH&Co.KGaA,Weinheim,Germany,2007)。
术语“互变异构体”或“互变异构形式”是指具有不同能量的可通过低能垒(lowenergy barrier)互相转化的结构异构体。若互变异构是可能的(如在溶液中),则可以达到互变异构体的化学平衡。例如,质子互变异构体(protontautomer)(也称为质子转移互变异构体(prototropic tautomer))包括通过质子迁移来进行的互相转化,如酮-烯醇异构化和亚胺-烯胺异构化。价键互变异构体(valence tautomer)包括通过一些成键电子的重组来进行的互相转化。酮-烯醇互变异构的具体实例是戊烷-2,4-二酮和4-羟基戊-3-烯-2-酮互变异构体的互变。互变异构的另一个实例是酚-酮互变异构。酚-酮互变异构的一个具体实例是吡啶-4-醇和吡啶-4(1H)-酮互变异构体的互变。除非另外指出,本发明化合物的所有互变异构体形式都在本发明的范围之内。
在本说明书的各部分,本发明公开化合物的取代基按照基团种类或范围公开。特别指出,本发明包括这些基团种类和范围的各个成员的每一个独立的次级组合。例如,术语“C1~6烷基”特别指独立公开的甲基、乙基、C3烷基、C4烷基、C5烷基和C6烷基。
在本发明的各部分,描述了连接取代基。当该结构清楚地需要连接基团时,针对该基团所列举的马库什变量应理解为连接基团。例如,如果该结构需要连接基团并且针对该变量的马库什基团定义列举了“烷基”或“芳基”,则应该理解,该“烷基”或“芳基”分别代表连接的亚烷基基团或亚芳基基团。
像本发明所描述的,本发明的化合物可以独立任选地被一个或多个取代基所取代,如上面的通式化合物,或者像实施例里面特殊的例子,子类,和本发明所包含的一类化合物。应了解“任选取代的”这个术语与“取代或非取代的”这个术语可以交换使用。一般而言,术语“独立任选地”不论是否位于术语“取代的”之前,表示所给结构中的一个或多个氢原子可以被具体取代基1所取代或未取代。除非其他方面表明,一个任选的取代基团可以有一个取代基1在基团的各个可取代的位置进行取代或未取代。当所给出的结构式中不只一个位置能被选自具体基团的一个或多个取代基1所取代,那么取代基可以相同或不同地在各个位置取代。其中所述的取代基1可以是,但并不限于:氧代(=O),氟,氯,溴,碘,羟基,氨基,羧基,烷基,卤代烷基,羟基烷基,氨基烷基,醛基,氨基酰基,烷氧基,氨基烷基,烷硫基,卤代烷氧基,氰基,芳基,杂芳基,烯基,炔基,杂环基,巯基,硝基,芳氧基,羟基烷氧基,苄基,环丙基,苯基,或烷氧基烷基等。在合理的情况下,取代基1能进一步被取代基2单取代或相同或不同的多取代。其中所述的取代基2可以是,但不限于:氧代(=O),氟,氯,溴,碘,羟基,氨基,羧基,烷基,卤代烷基,羟基烷基,氨基烷基,醛基,氨基酰基,烷氧基,氨基烷基,烷硫基,卤代烷氧基,氰基,芳基,杂芳基,烯基,炔基,杂环基,巯基,硝基,芳氧基,羟基烷氧基,苄基,环丙基,苯基,或烷氧基烷基等。
本发明使用的术语“烷基”包括1-20个碳原子饱和直链或支链的单价烃基,其中烷基可以独立独立任选地被一个或多个本发明所描述的取代基所取代。其中一些实施例是,烷基基团含有1-10个碳原子;另外一些实施例是,烷基基团含有1-8个碳原子;另外一些实施例是,烷基基团含有1-6个碳原子,另外一些实施例是,烷基基团含有1-4个碳原子;另外一些实施例是,烷基基团含有1-3个碳原子。烷基基团更进一步的实例包括,但并不限于,甲基(-CH3),乙基(-CH2CH3),正丙基(-CH2CH2CH3),异丙基(-CH(CH3)2),正丁基(-CH2CH2CH2CH3),2-甲基丙基或异丁基(-CH2CH(CH3)2),1-甲基丙基或仲丁基(-CH(CH3)CH2CH3),叔丁基(-C(CH3)3),正戊基(-CH2CH2CH2CH2CH3),2-戊基(-CH(CH3)CH2CH2CH3),3-戊基(-CH(CH2CH3)2),2-甲基-2-丁基(-C(CH3)2CH2CH3),3-甲基-2-丁基(-CH(CH3)CH(CH3)2),3-甲基-1-丁基(-CH2CH2CH(CH3)2),2-甲基-1-丁基(-CH2CH(CH3)CH2CH3),正己基(-CH2CH2CH2CH2CH2CH3),2-己基(-CH(CH3)CH2CH2CH2CH3),3-己基(-CH(CH2CH3)(CH2CH2CH3)),2-甲基-2-戊基(-C(CH3)2CH2CH2CH3),3-甲基-2-戊基(-CH(CH3)CH(CH3)CH2CH3),4-甲基-2-戊基(-CH(CH3)CH2CH(CH3)2),3-甲基-3-戊基(-C(CH3)(CH2CH3)2),2-甲基-3-戊基(-CH(CH2CH3)CH(CH3)2),2,3-二甲基-2-丁基(-C(CH3)2CH(CH3)2),3,3-二甲基-2-丁基(-CH(CH3)C(CH3)3),正庚基,正辛基,等等。术语“烷基”和其前缀“烷”在此处使用,都包含直链和支链的饱和碳链。烷基可以被本发明所述的取代基所取代。
术语“卤代烷基”表示烷基可以被一个或多个相同或不同卤素原子所取代的情况。其中烷基基团具有如本发明所述的含义,这样的实例包括,但并不限于三氟甲基,2,2-二氟乙基,3,3,3-三氟丙基等。卤代烷基可以被本发明所述的取代基所取代。
术语“氨基烷基”是指烷基可以被一个或多个相同或不同的氨基取代或者氨基分别独立地被一个或两个烷基基团所取代,其中烷基具有如本发明所述的含义。
本发明中所使用的术语“烷氧基”,涉及到烷基,像本发明所定义的,通过氧原子连接到主要的碳链上。这样的实施例包括,但并不限于,甲氧基,乙氧基,丙氧基等等。烷氧基可以被本发明所述的取代基所取代。
术语“环烷基”是指一价或多价、非芳香族、饱和或部分不饱和环,且不包含杂原子,其中包括3-12个碳原子的单环或7-12个碳原子的二环或三环。具有7-12个原子的双碳环可以是二环[4,5],[5,5],[5,6]或[6,6]体系,同时具有9或10个原子的双碳环可以是二环[5,6]或[6,6]体系。合适的环烷基基团包括,但并不限于,环烷基,环烯基和环炔基。环烷基基团的实例进一步包括,但绝不限于,环丙基,环丁基,环戊基,1-环戊基-1-烯基,1-环戊基-2-烯基,1-环戊基-3-烯基,环己基,1-环己基-1-烯基,1-环己基-2-烯基,1-环己基-3-烯基,环己二烯基,环庚基,环辛基,环壬基,环癸基,环十一烷基,环十二烷基,金刚烷基等等。视结构而定,环烷基可为单价基团或二价基团,即亚环烷基。C4环烷基是指环丁基,C5环烷基是指环戊基,C7环烷基是指环庚基。环烷基可以被本发明所述的取代基所取代。
术语“芳基”可以是单环,双环,和三环的碳环体系,其中,至少一个环体系是芳香族的,其中每一个环体系包含3-7个原子,且只有一个附着点与分子的其余部分相连。术语“芳基”可以和术语“芳香环”交换使用,如芳香环可以包括苯基,萘基和蒽。视结构而定,芳基可为单价基团或二价基团,即亚芳基。芳基可以被本发明所述的取代基所取代。
术语“杂芳基”,“杂芳环”在此处可交换使用,都是指单环,双环,三环或者四环体系,其中,双环杂芳环,三环杂芳环或者四环杂芳环体系以稠合的形式成环。其中,杂芳环体系至少一个环体系是芳香族的,环上一个或多个原子独立任选地被杂原子所取代(杂原子选自N,O,P,S,在此S或P独立任选地被一个或多个氧原子所取代得到像SO,SO2,PO,PO2的基团)。杂芳体系可以在任何杂原子或者碳原子上连接到主结构上从而形成稳定的化合物。杂芳体系基团可以是3-7个原子组成的单环,或7-10个原子组成的双环,或10-15个原子组成的三环。具有7-10个原子的双环可以是二环[4,5],[5,5],[5,6]或[6,6]体系,具有10-15个原子的三环可以是三环[5,5,6],[5,7,6]或[6,5,6]体系。
术语“杂环基”,“杂环”,“杂脂环族”或“杂环的”在此处可交换使用,都是指单环,双环,三环或者四环体系,其中环上一个或多个原子独立任选地被杂原子所取代,环可以是完全饱和的或包含一个或多个不饱和度,但绝不是芳香族类。杂环体系可以在任何杂原子或者碳原子上连接到主结构上从而形成稳定的化合物。一个或多个环上的氢原子独立任选地被一个或多个本发明所描述的取代基所取代。其中一些实施例是,“杂环基”,“杂环”,“杂脂环族”或“杂环的”基团是3-7元环的单环(1-6个碳原子和选自N,O,P,S的1-3个杂原子,在此S或P独立任选地被一个或多个氧原子所取代得到像SO,SO2,PO,PO2的基团,同时,-CH2-基团可以独立任选地被-C(=O)-替代;当所述的环为三元环时,其中只有一个杂原子),或7-10个原子组成的双环(4-9个碳原子和选自N,O,P,S的1-3个杂原子,在此N,S或P独立任选地被一个或多个氧原子所取代得到像NO,NO2,SO,SO2,PO,PO2的基团,同时,-CH2-基团可以独立任选地被-C(=O)-替代;)。
“杂环基”可以是碳基或杂原子基。“杂环基”同样也包括杂环基团与饱和或部分不饱和碳环或杂环并合所形成的基团。杂环的实例包括,但并不限于,吡咯烷基,四氢呋喃基,二氢呋喃基,四氢噻吩基,四氢吡喃基,二氢吡喃基,四氢噻喃基,哌啶基,噻噁烷基,氮杂环丁基,氧杂环丁基,硫杂环丁基,哌啶基,高哌啶基,环氧丙基,N-吗啉基,N-哌嗪基,2-哌嗪基,3-哌嗪基,高哌嗪基,氧氮杂卓基,二氮杂卓基,硫氮杂卓基,吡咯啉-1-基,2-吡咯啉基,3-吡咯啉基,二氢吲哚基,二氢苯并异噻嗪基,二氢苯并异噁嗪基,二氧戊环基,二氢吡嗪基,二氢吡啶基,二氢吡唑基,二氢嘧啶基,二氢吡咯基,呋喃酮基,呋喃基,咪唑烷基,咪唑啉基,咪唑基,咪唑并吡啶基,咪唑并噻唑基,吲唑基,,吲哚嗪基,吲哚基,吗啉基,噁唑烷二酮基,噁唑烷基,环氧乙烷基,哌嗪基,哌啶基,吡唑烷基,喹宁环基,四氢异喹啉基,四氢噻嗯基,硫吗啉基,噻唑烷基。
术语“螺环基”,“螺环”,“螺双环基”,“螺双环”表示一个环起源于另一个环上特殊的环状碳。例如,像下面所描述的,一个饱和的桥环体系(环D和B')被称为“稠合双环”,反之环A’和环D在两个饱和的环体系中共享一个碳原子,则被称为“螺环”。螺环里面的每一个环要么是碳环要么是杂脂环族。这样的实例包括,但并不限于,螺[2.4]庚烷-5-基,螺[4.4]壬烷基,等。
术语“螺杂双环基”表示一个环起源于另一个环上特殊的环状碳。例如,像上面所描述的,一个饱和的桥环体系(环D和B')被称为“稠合双环”,反之环A’和环D在两个饱和的环体系中共享一个碳原子,则被称为“螺环”。且至少一个环体系包含一个或多个杂原子,其中每一个环体系包含3-7个原子,即包含1-6个碳原子和选自N,O,P,S的1-3个杂原子,在此N,S或P独立任选地被一个或多个氧原子所取代得到像NO,NO2,SO,SO2,PO,PO2的基团,-CH2-基团可以独立任选地被-C(=O)-替代。
术语“稠合双环”,“稠环”,“稠合双环基”或“稠环基”表示饱和或不饱和的稠环体系,涉及到非芳香族的双环体系,至少有一个环是非芳香性的。这样的体系可以包含独立的或共轭的不饱和状态。稠合双环中的每一个环要么是碳环要么是杂脂环族,这样的实例包括,但并不限于,六氢-呋喃[3,2-b]呋喃基,2,3,3a,4,7,7a-六氢-1H-茚基,7-氮杂双环[2.2.1]庚烷基,稠合双环[3.3.0]辛烷基,稠合双环[3.1.0]己烷基,1,2,3,4,4a,5,8,8a-八氢萘基,1,2,3,4-四氢萘,2,3-二氢茚,这些都包含在稠合双环的体系之内。
术语“稠合杂双环基”表示饱和或不饱和的稠环体系,涉及到非芳香族的双环体系,至少有一个环是非芳香性的。这样的体系可以包含独立的或共轭的不饱和状态。且至少一个环体系包含一个或多个杂原子,其中每一个环体系包含3-7个原子组成的环,即包含1-6个碳原子和选自N,O,P,S的1-3个杂原子,在此N,S或P独立任选地被一个或多个氧原子所取代得到像NO,NO2,SO,SO2,PO,PO2的基团,-CH2-基团可以独立任选地被-C(=O)-替代。稠合杂双环基可以被本发明所述的取代基所取代。
如本发明所描述,取代基R’由一个键连接到中心的环上形成的环体系代表取代基R’可以在环上任何可取代或任何合理的位置进行取代。例如,式a代表A’环或B’环上任何可能被取代的位置均可被R’取代,如式b,式c,式d,式e,式f,式g,和式h所示。
如本发明所描述,附着点可以在环上任何可连接的位置与分子其余部分连接。例如,式i代表A’环或B’环上任何可能被连接的位置均可作为连接的点。
如本发明所描述,附着点可以在稠环上任何可连接的位置与分子其余部分连接,同时连接的两端可以互换。例如,式y代表环上任何可能被连接的位置均可作为连接的点,同时连接点的两端可以互换。
另外,需要说明的是,除非以其他方式明确指出,在本文中通篇采用的描述方式“各…和…独立地为”、“…和…各自独立地为”和“…和…分别独立地为”可以互换,应做广义理解,其既可以是指在不同基团中,相同符号之间所表达的具体选项之间互相不影响,也可以表示在相同的基团中,相同符号之间所表达的具体选项之间互相不影响。例如,“H-(C(R3)2)n-O-(C(R3)2)n1-C(=O)-(C(R3)2)n-”中“R3”表示相同或不同的基团,且相互之间不影响;“n”表示相同或不同的取值,且相互之间不影响。
术语“药学上可接受的”是指当给人施用时生理上可耐受的并且一般不产生过敏或相似不适当的反应,例如肠胃不适、眩晕等的分子实体和组合物。优选地,本文所用的术语“药学上可接受的”是指联邦监管机构或国家政府批准的或美国药典或其他一般认可的药典上列举的在动物中、更特别在人体中使用的。
术语“载体”指与所述化合物一同施用的稀释剂、辅剂、赋形剂或基质。这些药物载体可以是无菌液体,例如水和油类,包括石油、动物、植物或合成来源的,例如花生油、大豆油、矿物油、芝麻油等。水和水性溶液盐水溶液和水性葡萄糖与甘油溶液优选用作载体、特别是可注射溶液。适宜的药物载体描述于E.W.Martin的“Remington′s PharmaceuticalSciences”中。
本发明中立体化学的定义和惯例的使用通常参考以下文献:S.P.Parker,Ed.,McGraw-Hill Dictionary of Chemical Terms(1984)McGraw-Hill Book Company,NewYork;and Eliel,E.and Wilen,S.,"Stereochemistry of Organic Compounds",JohnWiley&Sons,Inc.,New York,1994.本发明的化合物可以包含不对称中心或手性中心,因此存在不同的立体异构体。本发明的化合物所有的立体异构形式,包括但绝不限于,非对映体,对映异构体,阻转异构体,和它们的混合物,如外消旋混合物,组成了本发明的一部分。很多有机化合物都以光学活性形式存在,即它们有能力旋转平面偏振光的平面。在描述光学活性化合物时,前缀D、L或R、S用来表示分子手性中心的绝对构型。前缀d、l或(+)、(-)用来命名化合物平面偏振光旋转的符号,(-)或l是指化合物是左旋的,前缀(+)或d是指化合物是右旋的。这些立体异构体的化学结构是相同的,但是它们的立体结构不一样。特定的立体异构体可以是对映体,异构体的混合物通常称为对映异构体混合物。50:50的对映体混合物被称为外消旋混合物或外消旋体,这可能导致化学反应过程中没有立体选择性或立体定向性。术语“外消旋混合物”和“外消旋体”是指等摩尔的两个对映异构体的混合物,缺乏光学活性。
“异构体”为具有相同分子式的不同化合物。“立体异构体”为仅仅原子的空间排列方式不同的异构体。如本文使用的术语“异构体”包括任何和所有的几何异构体和立体异构体。例如,“异构体”包括顺式和反式异构体、E-和Z-异构体、R-和S-对映异构体、非对映异构体、(d)异构体、(l)-异构体、其外消旋混合物、及落入本说明书范围的其它其混合物。
本发明的“水合物”是指本发明所提供的化合物或其盐,其还包括化学量或非化学当量通过非共价分子间力结合的水,也可说是溶剂分子是水所形成的缔合物。
本发明的“溶剂化物”是指一个或多个溶剂分子与本发明的化合物所形成的缔合物。形成溶剂化物的溶剂包括,但并不限于,水,异丙醇,乙醇,甲醇,二甲亚砜,乙酸乙酯,乙酸,氨基乙醇。
本发明的“氮氧化物”是指当化合物含几个胺官能团时,可将1个或大于1个的氮原子氧化形成N-氧化物。N-氧化物的特殊实例是叔胺的N-氧化物或含氮杂环氮原子的N-氧化物。可用氧化剂例如过氧化氢或过酸(例如过氧羧酸)处理相应的胺形成N-氧化物(参见Advanced Organic Chemistry,Wiley Interscience,第4版,Jerry March,pages)。尤其是,N-氧化物可用L.W.Deady的方法制备(Syn.Comm.1977,7,509-514),其中例如在惰性溶剂例如二氯甲烷中,使胺化合物与间-氯过氧苯甲酸(MCPBA)反应。
化合物可存在多种不同几何异构体和互变异构体,所述式(I)-式(III)化合物包括所有此类形式。为避免疑惑,当化合物以几种几何异构体或互变异构体之一存在并且只具体描述或显示一种时,显然所有其它形式包括在式(I)-式(III)中。
本发明所使用的术语“前药”,代表一个化合物在体内转化为式(I)-式(III)所示的化合物。这样的转化受前体药物在血液中水解或在血液或组织中经酶转化为母体结构的影响。本发明前体药物类化合物可以是酯,在现有的发明中酯可以作为前体药物的有苯酯类,脂肪族(C1-24)酯类,酰氧基甲基酯类,碳酸酯,氨基甲酸酯类和氨基酸酯类。例如本发明里的一个化合物包含羟基,即可以将其酰化得到前体药物形式的化合物。其他的前体药物形式包括磷酸酯,如这些磷酸酯类化合物是经母体上的羟基磷酸化得到的。关于前体药物完整的讨论可以参考以下文献:T.Higuchi and V.Stella,Pro-drugs as Novel DeliverySystems,Vol.14of the A.C.S.Symposium Series,Edward B.Roche,ed.,BioreversibleCarriers in Drug Design,American Pharmaceutical Association and PergamonPress,1987,J.Rautio et al,Prodrugs:Design and Clinical Applications,NatureReview Drug Discovery,2008,7,255-270,and S.J.Hecker et al,Prodrugs ofPhosphates and Phosphonates,Journal of Medicinal Chemistry,2008,51,2328-2345。
除非其他方面表明,本发明的化合物的所有互变异构形式都包含在本发明的范围之内。
“代谢产物”是指具体的化合物或其盐在体内通过代谢作用所得到的产物。一个化合物的代谢产物可以通过所属领域公知的技术来进行鉴定,其活性可以通过如本发明所描述的那样采用试验的方法进行表征。这样的产物可以是通过给药化合物经过氧化,还原,水解,酰氨化,脱酰氨作用,酯化,脱脂作用,酶裂解等等方法得到。相应地,本发明包括化合物的代谢产物,包括将本发明的化合物与哺乳动物充分接触一段时间所产生的代谢产物。
本发明化合物的各种药学上可接受的盐形式都是有用的。术语“药学上可接受的盐”是指那些盐形式对于制药化学家而言是显而易见的,即它们基本上无毒并能提供所需的药代动力学性质、适口性、吸收、分布、代谢或排泄。其他因素,在性质上更加实用,对于选择也很重要,这些是:原材料的成本、结晶的容易、产率、稳定性、吸湿性和结果原料药的流动性。简单地讲,药物组合物可以通过有效成分与药学上可接受的载体制备得到。
本发明所使用的“药学上可接受的盐”是指本发明的化合物的有机盐和无机盐。药学上可接受的盐在所属领域是为我们所熟知的,如文献:S.M.Berge et al.,describepharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences,66:1-19,1977.所记载的。药学上可接受的无毒的酸形成的盐包括,但并不限于,与氨基基团反应形成的无机酸盐有盐酸盐,氢溴酸盐,磷酸盐,硫酸盐,高氯酸盐,硝酸盐等,和有机酸盐如乙酸盐,丙酸盐,乙醇酸盐,草酸盐,马来酸盐,丙二酸盐,琥珀酸盐,富马酸盐,酒石酸盐,枸橼酸盐,苯甲酸盐,扁桃酸盐,甲磺酸盐,乙磺酸盐,甲苯磺酸盐,磺基水杨酸盐等,或通过书籍文献上所记载的其他方法如离子交换法来得到这些盐。
其他药学上可接受的盐包括己二酸盐、苹果酸盐、2-羟基丙酸、藻酸盐、抗坏血酸盐、天冬氨酸盐、苯磺酸盐、苯甲酸盐、重硫酸盐、硼酸盐、丁酸盐、樟脑酸盐、樟脑磺酸盐、环戊基丙酸盐、二葡萄糖酸盐、十二烷基硫酸盐、乙磺酸盐、甲酸盐、反丁烯二酸盐、葡庚糖酸盐、甘油磷酸盐、葡萄糖酸盐、半硫酸盐、庚酸盐、己酸盐、氢碘酸盐、2-羟基-乙磺酸盐、乳糖醛酸盐、乳酸盐、月桂酸盐、月桂基硫酸盐、苹果酸盐、丙二酸盐、甲磺酸盐、2-萘磺酸盐、烟酸盐、硝酸盐、油酸盐、棕榈酸盐、扑酸盐、果胶酸盐、过硫酸盐、3-苯基丙酸盐、苦味酸盐、特戊酸盐、丙酸盐、硬脂酸盐、硫氰酸盐、对甲苯磺酸盐、十一酸盐、戊酸盐、等等。通过适当的碱得到的盐包括碱金属,碱土金属,铵和N+(C1-4烷基)4的盐。
本发明也拟构思了任何所包含N的基团的化合物所形成的季铵盐。水溶性或油溶性或分散产物可以通过季铵化作用得到。碱金属或碱土金属盐包括钠盐、锂盐、钾盐、钙盐、镁盐、铁盐、锌盐、铜盐、锰盐、铝盐等等。药学上可接受的盐进一步包括适当的、无毒的铵,季铵盐和抗平衡离子形成的胺阳离子,如卤化物,氢氧化物,羧化物,硫酸化物,磷酸化物,硝酸化物,C1-8磺酸化物和芳香磺酸化物。胺盐,例如但不限于N,N’-二苄基乙二胺,氯普鲁卡因,胆碱,氨,二乙醇胺和其它羟烷基胺,乙二胺,N-甲基还原葡糖胺,普鲁卡因,N-苄基苯乙胺,1-对-氯苄基-2-吡咯烷-1’-基甲基-苯并咪唑,二乙胺和其它烷基胺,哌嗪和三(羟甲基)氨基甲烷;碱土金属盐,例如但不限于钡,钙和镁;过渡金属盐,例如但不限于锌。
在本说明书中,如果在化学名称和化学结构间存在任何差异,结构是占优的。
本发明所使用的任何保护基团、氨基酸和其它化合物的缩写,除非另有说明,都以它们通常使用的、公认的缩写为准,或参照IUPAC-IUB Commission on BiochemicalNomenclature(参见Biochem.1972,11:942-944)。
本发明提供药物组合物,包含治疗有效量的式(I)所示化合物或其药学上可接受的盐和药学上可接受的辅料、载体、赋形剂、溶媒或它们的组合。当本发明的化合物以药物的形式施用于哺乳动物例如人时,其可以以化合物本身的形式被给予或者可以以含有例如0.1至99.5%(更优选0.5至90%)活性成分以及药学可接受的载体的药物组合物的形式被给予。
“联合”表示在单个剂量单位形式中的固定组合或用于组合施用的部分的药盒,其中本发明公开化合物和组合伴侣(治疗肿瘤疾病、艾滋病、炎症反应以及免疫缺陷疾病的药物)可以在同一时间独立施用或者可以在一定的时间间隔内分别施用,特别是使联合合伴侣表现出合作、例如协同作用。如本文所用的术语“药物组合物”表示将一种以上活性成分混合或组合所得到的产品,并且既包括活性成分的固定组合也包括非固定组合。术语“固定联合”表示活性成分如本发明公开化合物和组合伙伴以单一实体或剂量的形式同时施用于患者。术语“非固定联合”表示活性成分如本发明公开化合物和组合伙伴均作为单独实体同时、共同或无特定时间限制地先后施用于患者。
措辞“药学可接受的载体”在本领域中是公认的,包括适于将本发明的化合物施用于哺乳动物的药学可接受的材料、组合物或载体。所述载体包括参与携带主题物质或将其从一个器官或机体的一部分转移到另一个器官或机体的另一部分的液体或固体填充剂、稀释剂、赋形剂、溶剂或包封材料。各载体在与制剂中的其它成分相容和对患者无害的意义上必须是“可接受的”。可用作药学可接受的载体的材料的一些实例包括:糖类,如乳糖、葡萄糖和蔗糖;淀粉类,如玉米淀粉和马铃薯淀粉;纤维素及其衍生物,如羧甲基纤维素钠、乙基纤维素和醋酸纤维素;粉状西黄蓍胶;麦芽;明胶;滑石粉;赋形剂,如可可脂和栓剂蜡类;油类,如花生油、棉子油、红花油、芝麻油、橄榄油、玉米油和豆油;二醇类,如丙二醇;多元醇类,如甘油、山梨醇、甘露醇和聚乙二醇;酯类,如油酸乙酯和月桂酸乙酯;琼脂;缓冲剂,如氢氧化镁和氢氧化铝;海藻酸;无热原的水;等张盐水;林格氏溶液;乙醇;磷酸盐缓冲液;和药物制剂中所用的其它无毒的可相容的物质。
在组合物中也可以存在润湿剂、乳化剂和润滑剂如十二烷基硫酸钠和硬脂酸镁,以及着色剂、释放剂、包衣剂、甜味剂、矫味剂和芳香剂、防腐剂和抗氧化剂。
药学可接受的抗氧化剂的实例包括:水溶性抗氧化剂,如抗坏血酸、盐酸半胱氨酸、硫酸氢钠、焦亚硫酸钠、亚硫酸钠等;油溶性抗氧化剂,如棕榈酸抗坏血酸酯、丁基化羟基苯甲醚(BHA)、丁化羟基甲苯(BHT)、卵磷脂、棓酸丙酯、α-生育酚等;和金属螯合剂,如柠檬酸、乙二胺四乙酸(EDTA)、山梨醇、酒石酸、磷酸等。
本发明的药物组合物包括适于口服、鼻、局部、口含、舌下、直肠和/或胃肠外施用的那些。制剂可以方便地以单位剂型形式存在并且可以通过药学领域公知的任何方法来制备。可以与载体物质组合来制备单剂量形式的活性成分的量一般是产生治疗作用的化合物的量。一般而言,以百分之一为单位,该量为约1%至约99%活性成分,优选约5%至约70%,最优选约10至约30%。
术语“治疗”用于指获得期望的药理学和/或生理学效果。所述效果就完全或部分预防疾病或其症状而言可以是预防性的,和/或就部分或完全治愈疾病和/或疾病导致的不良作用而言可以是治疗性的。本文使用的“治疗”涵盖哺乳动物、特别是人的疾病,包括:(a)在容易患病但是尚未确诊得病的个体中预防疾病或病症发生;(b)抑制疾病,例如阻滞疾病发展;或(c)缓解疾病,例如减轻与疾病相关的症状。本文使用的“治疗”涵盖将药物或化合物给予个体以治疗、治愈、缓解、改善、减轻或抑制个体的疾病的任何用药,包括但不限于将含本文所述化合物的药物给予有需要的个体。
下面将结合实施例对本发明的方案进行解释。本领域技术人员将会理解,下面的实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中未注明具体技术或条件的,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
实施例1
中间体71-2的合成:
将化合物71-1(500mg,2.92mmol)溶解在THF(30mL)和H2O 30mL中,加入碳酸氢钠(294mg,3.50mmol),二碳酸二叔丁酯(764mg,3.50mmol),室温搅拌。TLC跟踪反应,至原料氨甲环酸甲酯消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(PE:EA=3:1),得到中间体6-2(751mg)。
中间体71-2的合成:
将71-1(750mg,2.77mmol)溶解在THF(30mL)中,降温至0℃搅拌,慢慢加入LiAlH4(211mg,5.54mmol),搅拌,室温反应。TLC跟踪反应,至原料83-1消失,停止反应,饱和食盐水和EA萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(PE:EA=3:1),得到化合物83-2(754mg)。
中间体71-3的合成:
于100ml单口瓶中加入中间体71-2(750mg,3.08mmol),DMSO(10ml),IBX(1.04g,3.70mmol),室温下反应过夜,TLC监控。常规萃取操作浓缩,过柱纯化(PE:EA=1:2)得685mg黄色固体。
中间体71-4的合成:
将化合物71-3(650mg,2.70mmol)溶解在甲醇(30mL)中,搅拌,依次加入N-(3-氨丙基)环己胺(423mg,2.70mmol),氰基硼氢化钠(171mg,2.71mmol)和醋酸(163mg,2.71mmol),TLC跟踪反应,至原料71-4消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=10:1),得到中间体71-4(847mg)。
中间体71-5的合成:
将化合物71-4(840mg)溶解在2M HCl/CH3OH中,室温搅拌,TLC跟踪反应,至原料71-4消失,停止反应,浓缩除去溶剂,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=8:1),得到化合物71-5(677mg)。
中间体71-6的合成:
将N-Boc-L-丙氨酸(717mg,2.31mmol)溶解于THF(50mL)中,搅拌,依次加入HATU(1.05g,2.77mmol),HOBT(372mg,2.77mmol),DIEA(593mg,4.59mmol)和化合物71-5(650mg,2.31mmol),室温搅拌,TLC跟踪反应,至原料17-1消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱纯化(DCM:CH3OH=10:1),得到中间体71-6(836mg)。
中间体71-7的合成:
将化合物71-6(836mg)溶解在2M HCl/CH3OH中,室温搅拌,TLC跟踪反应,至原料71-6消失,停止反应,浓缩除去溶剂,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,得到化合物71-7(654mg)。
终产物NIC71的合成:
将化合物71-7(600mg,1.70mmol)溶解在甲醇(30mL)中,搅拌,依次加入吡啶-2-甲醛(183mg,1.70mmol),氰基硼氢化钠(129mg,2.05mmol)和醋酸(141mg,2.33mmol),TLC跟踪反应,至原料71-7消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到白色固体终产物NIC71(359mg)。
化合物NIC71:1H NMR(400MHz,CDCl3)δ8.59(d,J=3.8Hz,1H),7.66(t,J=7.6Hz,1H),7.52(s,1H),7.21(d,J=7.7Hz,2H),3.87(d,J=4.6Hz,2H),3.30–3.19(m,1H),3.12(t,J=6.4Hz,2H),2.69(dt,J=18.2,6.6Hz,4H),2.45(d,J=6.3Hz,3H),1.89(d,J=11.4Hz,3H),1.85–1.57(m,10H),1.56–1.39(m,3H),1.36(d,J=6.9Hz,3H),1.33–0.86(m,10H)。
HRMS(ESI,m/z):444.3713。
参考上述合成路线合成下表所示的化合物:
实施例2
中间体96-2的合成:
将化合物96-1(400mg,0.84mmol)溶解在10Ml THF中,依次加入2,4-二氯嘧啶(125mg,0.84mmol)和DIEA(129mg,1.00mmol),室温搅拌,TLC跟踪反应,至原料96-1消失,停止反应,饱和食盐水和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=30:1),得到黄色固体终产物96-2(392mg)。
中间体96-3的合成:
将化合物96-2(390mg,0.66mmol)溶解在20Ml 1,4-二氧六环中,依次加入2-氨甲基吡啶(71mg,0.66mmol),碳酸铯(323mg,0.99mmol)和[1,1’-双(二苯基膦基)二茂铁]二氯化钯(48mg,0.066mmol),N2置换,加热至100℃反应。TLC跟踪反应,至原料96-2消失,停止反应,饱和食盐水和DCM萃取号西苑广场三楼、电脑城3楼)三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=30:1),得到黄色固体终产物96-3(268mg)。
终产物NIC96的合成:
将化合物96-3(260mg)溶解在2M HCl/CH3OH中,室温搅拌,TLC跟踪反应,至原料32-4消失,停止反应,浓缩除去溶剂,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱坐公交车到童诺迷你世界)纯化(DCM:CH3OH=10:1),得到终产物NIC32(168mg)。
化合物NIC32:HRMS(ESI,m/z):460.3192。
参考上述合成路线合成下表所示的化合物:
实施例3
中间体17-2合成:
将N-Fmoc-L-丙氨酸(295mg,0.95mmol)溶解于THF(20Ml)中,搅拌,依次加入HATU(431mg,1.14mmol),HOBT(153mg,1.14mmol),DIEA(244mg,1.89mmol)和化合物17-1(528mg,0.95mmol),室温搅拌,TLC跟踪反应,至原料17-1消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱纯化(PE:EA=3:1),得到中间体17-2(679mg)。
中间体17-3合成:
将化合物17-2(650mg)溶解在1M PIP/THF溶液中,室温搅拌。TLC跟踪反应,至原料17-2消失,停止反应,浓缩过柱纯化(DCM:CH3OH=10:1),得到中间体17-3(451mg)。
中间体17-4合成:
将化合物17-3(450mg,0.82mmol)溶解在甲醇(20Ml)中,搅拌,依次加入2-乙酰基吡啶(100mg,0.82mmol),氰基硼氢化钠(103mg,1.64mmol)和醋酸(98mg,1.64mmol),TLC跟踪反应,至原料17-3消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到中间体17-4(389mg)。
化合物NIC17的合成:
将化合物17-4(350mg)溶解在2M HCl/CH3OH中,室温搅拌,TLC跟踪反应,至原料17-4消失,停止反应,浓缩除去溶剂,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=8:1),得到化合物NIC17(139mg)。
化合物NIC17:1H NMR(400MHz,DMSO)δ9.50(s,1H),8.80(t,J=5.7Hz,1H),8.69(d,J=4.2Hz,1H),7.89(td,J=7.7,1.7Hz,1H),7.46(dd,J=10.7,8.2Hz,3H),7.30(dd,J=17.0,8.1Hz,2H),4.51(s,1H),4.35(dd,J=11.6,5.9Hz,2H),4.16(s,2H),3.67(s,2H),3.00(s,5H),1.99(s,4H),1.77(s,2H),1.62(d,J=11.3Hz,1H),1.53(t,J=6.2Hz,3H),1.42(t,J=6.0Hz,3H),1.25(t,J=10.0Hz,6H)。
HRMS(ESI,m/z):452.3393。
参考上述合成路线合成下表所示的化合物:
实施例4
中间体6-1的合成:
将化合物N-叔丁氧羰基-1,3-丙二胺(500mg,2.87mmol)溶解在40Ml甲醇中,室温搅拌,加入4-氰基苯甲醛(375mg,2.87mmol),室温搅拌1h,加入氰基硼氢化钠(218mg,3.44mmol)和冰醋酸(206mg,3.44mmol),室温搅拌。TLC跟踪反应,至原料N-叔丁氧羰基-1,3-丙二胺消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到中间体6-1(948mg)。
中间体6-2的合成:
将化合物6-1(900mg,3.11mmol)溶解在THF(20Ml)和H2O 20Ml中,加入碳酸氢钠(270mg,3.22mmol),二碳酸二叔丁酯(678mg,3.11mmol),,室温搅拌。TLC跟踪反应,至原料N-叔丁氧羰基-1,3-丙二胺消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(PE:EA=3:1),得到中间体6-2(1.3g)。
中间体6-3的合成:
将化合物6-2(1g)溶解在甲醇中,加入10%的Rany Ni,H2置换三次。室温搅拌反应。TLC跟踪反应,至原料6-2消失,停止反应,过滤,浓缩,得到中间体6-3(989mg)。
中间体6-4的合成:
将化合物6-3(980mg,2.49mmol)溶解于THF(20Ml)中,搅拌,依次加入HATU(941mg,2.49mmol),HOBT(334mg,2.49mmol),DIEA(1.01g,4.13mmol)和化合物N-芴甲氧羰基-L-丙氨酸五氟苯酯(1.19g,2.49mmol),室温搅拌,TLC跟踪反应,至原料6-3消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱纯化(PE:EA=3:1),得到中间体6-4(1.5g)。
中间体6-5的合成:
将化合物6-5(1.5g)溶解在20%PIP/THF溶液中,室温搅拌反应。TLC跟踪反应,至原料6-5消失,停止反应,浓缩,过柱纯化(DCM:CH3OH=20:1),得到中间体6-3(972mg)。中间体6-6的合成:
将化合物6-6(900mg,1.94mmol)溶解在甲醇(30Ml)中,搅拌,依次加入吡啶-2-甲醛(208mg,1.94mmol),氰基硼氢化钠(147mg,2.33mmol)和醋酸(141mg,2.33mmol),TLC跟踪反应,至原料6-6消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到中间体6-6(879mg)。
中间体6-7的合成:
将化合物6-5(850mg)溶解在2M HCl/CH3OH中,室温搅拌,TLC跟踪反应,至原料6-5消失,停止反应,浓缩除去溶剂,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=8:1),得到化合物6-7(458mg)。
终产物NIC6的合成:
将化合物6-7(400mg,1.13mmol)溶解在甲醇(30Ml)中,搅拌,依次加入4,4-二氟环已酮(151mg,1.13mmol),氰基硼氢化钠(86mg,1.36mmol)和醋酸(82mg,1.36mmol),TLC跟踪反应,至原料6-7消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到终产物NIC6(268mg)。
化合物NIC6:1H NMR(400MHz,DMSO)δ9.46(s,1H),8.96(s,1H),8.69(d,J=4.2Hz,1H),7.94(td,J=7.7,1.7Hz,1H),7.57–7.46(m,3H),7.38(d,J=8.1Hz,2H),4.43(d,J=5.4Hz,2H),4.35(d,J=9.7Hz,2H),4.18(s,2H),4.06(d,J=6.8Hz,1H),3.25(s,1H),3.06(s,4H),2.12(d,J=13.3Hz,4H),2.06–1.99(m,2H),1.92(dd,J=22.7,8.9Hz,2H),1.62(d,J=10.9Hz,2H),1.53(d,J=7.0Hz,3H)。
HRMS(ESI,m/z):474.3074。
参考上述合成路线合成下表所示的化合物:
实施例5
中间体83-1的合成:
将2-哌嗪酮(400mg,3.00mmol)溶解在甲醇(30Ml)中,搅拌,依次加入吡啶-2-甲醛(321mg,3.00mmol),氰基硼氢化钠(227mg,3.60mmol)和醋酸(216mg,3.60mmol),TLC跟踪反应,至原料2-哌嗪酮消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到化合物83-1(587mg)。
中间体83-2的合成:
将83-1(580mg,3.03mmol)溶解在THF(30Ml)中,降温至0℃搅拌,慢慢加入NaH(145mg,6.06mmol),搅拌30min,加入4-溴甲基苯甲醛(603mg,3.03mmol),室温反应。TLC跟踪反应,至原料83-1消失,停止反应,饱和食盐水和EA萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(PE:EA=3:1),得到化合物83-2(754mg)。
终产物NIC83的合成:
将化合物83-2(700mg,2.26mmol)溶解在甲醇(30Ml)中,搅拌,依次加入N-(3-氨丙基)环己胺(354mg,2.26mmol),氰基硼氢化钠(171mg,2.71mmol)和醋酸(163mg,2.71mmol),TLC跟踪反应,至原料83-2消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=10:1),得到终产物NIC83(468mg)。
化合物NIC83:1H NMR(400MHz,DMSO)δ8.50(dt,J=8.4,2.6Hz,1H),7.77(td,J=7.7,1.8Hz,1H),7.43(d,J=7.8Hz,1H),7.34–7.25(m,3H),7.16(d,J=8.0Hz,2H),4.48(s,2H),3.71–3.60(m,5H),3.22–3.15(m,3H),3.14(s,2H),2.70–2.63(m,2H),2.58–2.53(m,2H),2.32(d,J=12.5Hz,2H),1.77(d,J=10.2Hz,2H),1.63(d,J=12.1Hz,2H),1.52(dd,J=13.6,6.7Hz,3H),1.25–1.06(m,4H),0.95(d,J=11.1Hz,2H)。
HRMS(ESI,m/z):450.3232。
参考上述合成路线合成下表所示的化合物:
实施例6
中间体32-2的合成:
将N-Fmoc-L-丙氨酸(271mg,0.87mmol)将溶解于THF(50Ml)中,搅拌,依次加入HATU(400mg,1.04mmol),HOBT(141mg,1.04mmol),DIEA(225mg,1.74mmol)和中间体32-1(400mg,0.87mmol),室温搅拌,TLC跟踪反应,至原料17-1消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱纯化(DCM:CH3OH=10:1),得到中间体71-6(512mg)
中间体32-3的合成:
将化合物32-2(500mg)溶解在20%PIP/THF溶液中,室温搅拌。TLC跟踪反应,至原料32-2消失,停止反应,浓缩过柱纯化(DCM:CH3OH=10:1),得到中间体32-3(368mg)。
中间体32-4的合成:
将3-吡啶磺酸(102mg,0.64mmol)将溶解于THF(50Ml)中,搅拌,依次加入HATU(296mg,0.77mmol),HOBT(104mg,0.77mmol),DIEA(167mg,1.29mmol)和中间体32-3(350mg,0.64mmol),室温搅拌,TLC跟踪反应,至原料32-3消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱纯化(DCM:CH3OH=10:1),得到中间体32-4(385mg)。
终产物NIC32的合成:
将化合物32-4(380mg)溶解在2M HCl/CH3OH中,室温搅拌,TLC跟踪反应,至原料32-4消失,停止反应,浓缩除去溶剂,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱纯化(DCM:CH3OH=10:1),得到终产物NIC32(168mg)。
化合物NIC32:1H NMR(400MHz,DMSO)δ9.57(s,1H),8.79(t,J=5.7Hz,1H),8.69(d,J=4.2Hz,1H),7.89(td,J=7.7,1.7Hz,1H),7.46(dd,J=10.7,8.2Hz,3H),7.30(dd,J=17.0,8.1Hz,2H),4.51(s,1H),4.35(dd,J=11.6,5.9Hz,2H),4.16(s,2H),3.67(s,2H),3.00(s,5H),1.99(s,4H),1.77(s,2H),1.53(t,J=6.2Hz,3H),1.42(t,J=6.0Hz,3H),1.25(t,J=10.0Hz,3H).
HRMS(ESI,m/z):488.3105。
参考上述合成路线合成下表所示的化合物:
实施例7
中间体40-1的合成:
将化合物2-氨甲基吡啶(500mg,4.64mmol)溶解在40Ml甲醇中,室温搅拌,加入4-氰基苯甲醛(606mg,4.64mmol),室温搅拌1h,加入氰基硼氢化钠(353mg,5.57mmol)和冰醋酸(334mg,5.57mmol),室温搅拌。TLC跟踪反应,至原料4-氰基苯甲醛消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到中间体40-2(756mg)。
中间体40-2的合成:
将化合物40-1(750mg)溶解在甲醇中,加入10%的Rany Ni,H2置换三次。室温搅拌反应。TLC跟踪反应,至原料40-1消失,停止反应,过滤,浓缩,得到中间体40-2(587mg)。
中间体40-3的合成:
将N-Fmoc-L-丙氨酸(548mg,1.76mmol)将溶解于THF(50Ml)中,搅拌,依次加入HATU(808mg,2.10mmol),HOBT(285mg,2.10mmol),DIEA(455mg,3.51mmol)和中间体40-2(400mg,1.76mmol),室温搅拌,TLC跟踪反应,至原料40-2消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩过柱纯化(DCM:CH3OH=10:1),得到中间体40-3(775mg)。
中间体40-4的合成:
将化合物40-3(770mg)溶解在20%PIP/THF溶液中,室温搅拌。TLC跟踪反应,至原料40-3消失,停止反应,浓缩过柱纯化(DCM:CH3OH=10:1),得到中间体40-4(440mg)。
终产物NIC40的合成:
将化合物40-4(400mg,1.34mmol)溶解在甲醇(30Ml)中,搅拌,依次加入吡啶-2-甲醛(145mg,1.34mmol),氰基硼氢化钠(102mg,1.62mmol)和醋酸(111mg,1.84mmol),TLC跟踪反应,至原料40-4消失,停止反应,饱和碳酸氢钠和DCM萃取三次,合并有机相,无水硫酸钠干燥,浓缩,过柱纯化(DCM:CH3OH=20:1),得到白色固体终产物NIC40(126mg)。
化合物NIC40:1H NMR(400MHz,DMSO)δ8.76(s,1H),8.63(d,J=4.8Hz,1H),8.56(d,J=4.7Hz,1H),7.85(dtd,J=21.6,7.7,1.7Hz,2H),7.45(ddd,J=12.5,9.4,5.9Hz,5H),7.37–7.29(m,3H),4.36(d,J=6.0Hz,2H),4.22(s,2H),4.15(s,2H),4.01(s,2H),3.55(t,J=15.5Hz,1H),1.34(d,J=6.8Hz,3H)。
HRMS(ESI,m/z):390.2295。
参考上述合成路线合成下表所示的化合物:
实施例8CXCR4生物活性实验
1、化合物对CXCR4的亲和活性测试
(1)实验方法
CXCR4的亲和活性检测所用的细胞系为体外构建的稳定转染CXCR4的CHO细胞系。CHO细胞系经DMEM培养基(含10%胎牛血清,100IU青霉素,0.1mg/ml的链霉素和0.2mg/ml的G418)培养,胰蛋白酶消化后,清洗计数后用FACS缓冲液(含0.5%BSA,0.05%NaN3的PBS)悬浮细胞,加入96孔板中。每孔的反应体系共100μl,包含5×105个细胞,250ng/ml的12G5单抗以及不同浓度的检测的化合物。冰上孵育40min后,用FACS缓冲液洗涤后,加入抗鼠的FITC标记的IgG二抗(1:200)后冰上孵育30min,用FACS缓冲液洗涤两次,酶标仪(PerkinElmer)检测485nmEX/535nmEM的吸收,记录荧光强度值。计算每个化合物抑制12G5单抗与受体CXCR4结合的比例,即在0.1μM浓度下的结合抑制率。
(2)实验结果
部分化合物的亲和活性IC50值如下表1所示,化合物活性数值分为以下几个区间:A:1-20nM,B:20-50nM,C:50-100nM,D:100-500nM。可以看出,本发明的化合物表现出较强抑制活性。
表1化合物的亲和活性实验结果
2、化合物抑制SDF-1α诱导的细胞迁移实验
(1)实验方法
SDF-1α诱导的细胞迁移实验是用天然表达CXCR4的SupT1细胞系检测的。首先收集RPMI 1640(含10%胎牛血清,100IU青霉素和0.1mg/ml的链霉素)培养的悬浮的SupT1细胞,用含0.5%BSA的RPMI 1640洗涤后计数,悬浮细胞至每毫升3.0×107个细胞,细胞和不同浓度的化合物混匀后,取75μl加入至tranwell小室中,37℃孵育30min后,在下层培养板的孔内加入200μl含2Nm SDF-1α的0.5%BSA的RPMI 1640(背景值的一组不含SDF-1α),37℃孵育3小时后,去除上层的tranwell小室,在下层培养孔中每孔加入40μl的CellTiter 96(Promega),孵育1-4小时后检测490nm处的吸收值。每组实验结果均经过至少三次的独立实验得到,抑制曲线由GraphPad软件制作。
(2)实验结果
如表2中所示,100%>A>70%,70%>B>30%,30%>C。在SDF-1α诱导的细胞迁移抑制实验中,本发明的化合物在500nM浓度下,具有显著的抑制细胞迁移能力。
表2 SDF-1α诱导的细胞迁移实验结果
3、血浆蛋白稳定性实验
(1)实验方法
用乙腈将溴丙胺太林(propantheline bromide)稀释到1mM。用propanthelinebromide作为human的对照药。分别取4μL 10mM待测药加入到96孔板中,再加入36μL DMSO将待测药稀释到1mM。
将-80℃保存的人血浆置于37℃水浴中解冻,4,000rpm离心10分钟,去除漂浮物和凝块。用pH计检测血浆pH值,仅使用pH7.2-8.0的血浆。将血浆置于37℃水浴中预孵育15分钟。取398μL预孵育的血浆加入新的96孔板中,分别加入2μL待测化合物和对照药,化合物终浓度为5μM,有机溶剂浓度为0.2%,每个化合物2个平行。将样品涡旋混匀后放置在37℃水浴中,50rpm孵育。分别在孵育0、10、30、60、90和120分钟后各取出50μL样品至96孔板中,加入400μL含内标乙腈(100nM aprozolam,200nM caffeine,100nM tolbutamide),涡旋10分钟后,于4,000rpm离心30min。吸取上清液300μL至新的96孔板中,于4,000rpm再次离心30min。吸取二次离心的上清液150μL,与等体积水混合稀释之后进行LC-MS/MS分析。
(2)实验结果
如表3中所示,在人源血浆蛋白稳定性实验中,与对照药Propantheline相比,化合物NIC80在2小时的血浆蛋白稳定性实验中表现出很好的稳定性。
表3血浆蛋白稳定性实验结果
4、体内动员实验和化疗药物增敏实验
(1)实验方法
使用带有高度表达CXCR4和EGFP-Luc(荧光素酶报告基因)的急性髓细胞白血病(AML)的细胞系U937构建的异体瘤模型NSG小鼠。给模式小鼠注射5mg/kg剂量的NIC108化合物,并在不同时间点取外周血,用CD45-PE和12G5-APC抗体标记动员出的AML细胞,并用流式细胞仪检测AML细胞数量。使用已上市的CXCR4拮抗剂AMD3100作为阳性对照。
在AML异体瘤模型小鼠注射10mg/kg的NIC108,并在注射后的3小时内给小鼠50mg/kg的阿糖胞苷,隔天给药连续给药7次,并在第14天给小鼠注射荧光素酶,检测小鼠体内的AML细胞量。
(2)实验结果
如图1左所示,NIC108可有效动员小鼠骨髓中的AML细胞到外周血中,效果与阳性对照药物AMD3100相类似。图1右可见NIC108可有效动员骨髓内AML细胞到外周血,并可大大提升阿糖胞苷杀死肿瘤细胞的效果。
5、干细胞动员实验
(1)实验方法
在NSG小鼠皮下注射NIC108,剂量为5mg/kg,在注射后的5分钟,15分钟,30分钟,1小时和2小时取小鼠外周血,破红细胞后,将剩余血细胞种植于干细胞培养的半固体培养基中。37度培养14天后,使用体视显微镜计数由造血干细胞和祖细胞形成的集落数量(CFU)。使用已上市的CXCR4拮抗剂AMD3100作为阳性对照。
(2)实验结果
由图2所示,NIC108可有效动员NSG小鼠骨髓中的造血干细胞和造血祖细胞,效果优于已上市药物AMD3100。
在本说明书的描述中,参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不必须针对的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任一个或多个实施例或示例中以合适的方式结合。此外,在不相互矛盾的情况下,本领域的技术人员可以将本说明书中描述的不同实施例或示例以及不同实施例或示例的特征进行结合和组合。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (10)
1.一种化合物,其特征在于,为如式(I)所示的化合物、其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或者前药:
L选自C2~10烯基、C2~10炔基、C3~8环烷基、C3~6杂环基、芳基、C1~5杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基或者C1~12螺杂环基,或者L、及与相连的N及R2形成环状结构;
R1选自键、氢、磺酰基、亚磺酰基、C1~6烷基磺酰基、氨基C1~6烷基、C1~6烷基亚磺酰基、羰基、C1~6烷基羰基、氨基酸、酰胺键、 或者其中A、B、C、D、E、F、G各自独立地为C、N、O、S原子,或者中的C、N及R7形成环状结构,或者R1与R2以及连接的同一N原子形成环状结构;或者R2、N、和L形成环状结构;
R2、R3和R4各自独立地选自氢、羟基、氨基、磺酰基、亚磺酰基、羰基、C1~6烷基、C2~10烯基、C2~10炔基、C1~6烷氧基、氨基C1~6烷基、C1~6烷基磷酰基、C1~6烷基羰基、C3~8环烷基、C3~8杂环基、芳基、C1~10杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基或者C1~12螺杂环基;或者R3、R4、及与两端相连的N原子之间形成环;
R5和R6各自独立地选自氢、磺酰基、亚磺酰基、羰基、氨基、C1~10烷基、C2~10烯基、C2~10炔基、C1~6烷氧基、氨基C1~6烷基、C1~6烷基磷酰基、C1~6烷基羰基、C1~6烷基芳基、C3~8环烷基、C3~8杂环基、C1~4烷基C3~8杂环基、芳基、C1~10杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基或者C1~12螺杂环基;
R7选自氢、氨基、磺酰基、亚磺酰基、羰基、C1~6烷基、C2~10烯基、C2~10炔基、C1~6烷氧基、氨基C1~6烷基、C1~6烷基磷酰基、C1~6烷基羰基、C1~6烷基芳基、C3~8环烷基、C3~8杂环基、芳基、C1~10杂芳基、C1~12稠合环基、C1~12稠合杂环基、C1~12螺环基、C1~12螺杂环基;
其中,
所述烯基、炔基、烷氧基、氨基、烷基、氨基烷基、环烷基、烷基磷酰基、杂环基、芳基、杂芳基、烷基羰基、烷基杂环基、烷基芳基、稠合环基、稠合杂环基、螺环基、螺杂环基、磺酰基和亚磺酰基可分别独立地被一个或者多个烷基、烯基、炔基、氟、氯、溴、碘、卤代烷基、卤代芳基、卤代杂芳基、羟基、氨基、羰基、羧基、胍基、脒基、磺酰基、亚磺酰基、烷氧基、氨基烷基、烷基磷酰基、烷基羰基、环烷基、杂环基、芳基、杂芳基、稠合环基、稠合杂环基、螺环基、螺杂环基所取代;
n1、n2和n3各自独立地为0~10的整数。
R2选自氢、C1~6烷基、C3~6环烷基、C3~6杂环基、氨基C1~4烷基或C1~5杂芳基,所述烷基、环烷基、杂环基、氨基烷基或杂芳基可任选的被一个或多个H、C1~4烷基、氟、氯、溴、碘、氨基或C1~5杂芳基所取代;
R5选自C1~6烷基、芳基、C3~6环烷基、C3~6杂环基或C1~5杂芳基,其中,所述烷基、环烷基、杂环基、芳基或杂芳基可任选地被一个或多个氟、氯、溴、碘、C1~6烷基、C1~6环烷基、芳基、C1~5杂芳基或C1~6杂环基取代;
R6选自C1~4烷基、氨基、磺酰基、亚磺酰基、羰基、氨基C1~6烷基、C1~6烷基芳基、C1~4烷基C3~8杂芳环基、C3~6环烷基或C3~6杂环基,其中,所述烷基、氨基、羰基、磺酰基、亚磺酰基、氨基烷基、烷基芳基、烷基杂环基、环烷基或杂环基可任选地被一个或多个氢、氟、氯、溴、碘、氨基、芳基、C1~5杂芳基、卤代C1~5杂芳基、C2~6杂环基或C1~4烷基磷酰基取代;
R7选自C1~6烷基、芳基、C1~6烷基芳基、C1~5杂芳基、C1~6烯基、C3~6环烷基、C3~6杂环基、磺酰基或亚磺酰基,所述烷基、芳基、杂芳基、烷基芳基、烯基、环烷基或杂环基可任选地被一个或多个氢、氟、氯、溴、碘、C1~6烷基、C3~6环烷基、芳基、C1~5杂芳基、脒基、胍基或氨基所取代;
(1)所述芳基上碳原子被非氢基的取代基所取代;
(4)R5为环烷基,所述环烷基被一个或多个氟、氯、溴、碘、羟基、氨基、芳基、C1~4烷基、C1~8环烷基或C1~8杂环基所取代;
(5)R6为羰基、磺酰基、亚磺酰基、氨基或氨基C1~4烷基,所述羰基、磺酰基、亚磺酰基、氨基或氨基C1~4烷基可任选地被一个或多个氢、氟、氯、溴、碘、氨基、芳基、C1~5杂芳基、卤代C1~5杂芳基、C2~6杂环基或C1~4烷基磷酰基取代;
(6)R7为C1~4烷基、C1~4烯基、C1~5杂芳基或C3~6环烷基,其中,所述烷基不可被烷基、脒基、氨基、C1~5杂芳基所取代。
7.权利要求1~6任一项所述化合物在制备药物中的用途,其特征在于,所述药物用于治疗肿瘤疾病、艾滋病、骨髓移植、镰状细胞性贫血、造血干细胞移植、创伤、心肌梗死、嗜中性白血球减少症、缺血性疾病、神经性疾病、视网膜静脉阻塞、呼吸系统性疾病、肠胃疾病、皮肤疾病、炎症反应或免疫缺陷疾病;
任选地,所述药物抑制CXCR4的表达或者阻断CXCR4和SDF-1α之间的相互作用;
任选地,所述药物用于动员骨髓中的造血干细胞以用于自体或异体造血干细胞移植,用于多发性骨髓瘤和非霍杰金淋巴瘤疾病的治疗;
任选地,所述药物用于动员骨髓中的干细胞,用于白血病的治疗;
任选地,所述药物用于动员骨髓中的急性髓细胞白血病的癌细胞到外周血,用于白血病的治疗;
任选地,所述药物抑制肿瘤细胞转移,用于肿瘤的治疗;
任选地,所述药物抑制HIV-1入侵T细胞,用于艾滋病的治疗;
任选地,所述药物用于自身免疫缺陷疾病的治疗;
任选地,所述药物在制备造血干细胞/祖细胞动员剂和/或在过表达CXCR4的肿瘤组织中作为检测肿瘤标志物的应用。
8.一种药物组合物,其特征在于,包括权利要求1~6任一项所述化合物;
任选地,所述药物组合物进一步包括药学上可接受的辅料、载体、赋形剂、溶媒或它们的组合;
任选地,所述药物组合物进一步包含治疗剂,所述治疗剂选自下列的至少之一:马拉韦罗、恩夫韦肽、齐多夫定、扎西他宾、司他夫定、拉米夫定、萘韦拉平、地拉韦定、阿巴卡韦、依非韦伦、替诺福韦、乙曲西他槟、依曲韦润、利匹韦润、顺铂、环磷酰胺、阿糖胞苷、5-氟尿嘧啶、吉西他滨、紫杉醇、多西他赛、阿霉素、格列卫、特罗凯、索拉菲尼、达沙替尼、拉帕替尼、舒尼替尼、埃罗替尼、吉非替尼、Tisagenlecleucel、益基利仑赛、阿仑单抗、阿特珠单抗、阿维单抗、伊匹单抗、奥法木单抗、纳武利尤单抗、帕博利珠单抗、利妥昔单抗、度伐鲁单抗、卡瑞利珠单抗、特伦普利单抗、信迪利单抗、替雷利珠单抗、阿替利珠单抗、西妥昔单抗和曲妥珠单抗的赫赛汀。
9.一种药物联合,其特征在于,包含:
权利要求1~6任一项所述化合物或权利要求8所述药物组合物;以及
一种或多种用于治疗肿瘤疾病、艾滋病、炎症反应以及免疫缺陷疾病的药物;
任选地,所述药物选自下列的至少之一:马拉韦罗、恩夫韦肽、齐多夫定、扎西他宾、司他夫定、拉米夫定、萘韦拉平、地拉韦定、阿巴卡韦、依非韦伦、替诺福韦、乙曲西他槟、依曲韦润、利匹韦润、顺铂、环磷酰胺、阿糖胞苷、5-氟尿嘧啶、吉西他滨、紫杉醇、多西他赛、阿霉素、格列卫、特罗凯、索拉菲尼、达沙替尼、拉帕替尼、舒尼替尼、埃罗替尼、吉非替尼、Tisagenlecleucel、益基利仑赛、阿仑单抗、阿特珠单抗、阿维单抗、伊匹单抗、奥法木单抗、纳武利尤单抗、帕博利珠单抗、利妥昔单抗、度伐鲁单抗、卡瑞利珠单抗、特伦普利单抗、信迪利单抗、替雷利珠单抗、阿替利珠单抗、西妥昔单抗或曲妥珠单抗的赫赛汀。
10.一种药物载体,其特征在于,包括权利要求1~6任一项所述化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811626331 | 2018-12-28 | ||
CN2018116263310 | 2018-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111377854A true CN111377854A (zh) | 2020-07-07 |
CN111377854B CN111377854B (zh) | 2022-03-29 |
Family
ID=71128825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911380346.8A Active CN111377854B (zh) | 2018-12-28 | 2019-12-27 | Cxcr4抑制剂及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111377854B (zh) |
WO (1) | WO2020135765A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101242848A (zh) * | 2005-06-14 | 2008-08-13 | 太景生物科技股份有限公司 | 嘧啶化合物 |
CN107602450A (zh) * | 2017-09-28 | 2018-01-19 | 清华大学 | 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用 |
-
2019
- 2019-12-27 WO PCT/CN2019/129362 patent/WO2020135765A1/zh active Application Filing
- 2019-12-27 CN CN201911380346.8A patent/CN111377854B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101242848A (zh) * | 2005-06-14 | 2008-08-13 | 太景生物科技股份有限公司 | 嘧啶化合物 |
CN107602450A (zh) * | 2017-09-28 | 2018-01-19 | 清华大学 | 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2020135765A1 (zh) | 2020-07-02 |
CN111377854B (zh) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102533599B1 (ko) | 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 | |
CN108699032A (zh) | 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途 | |
CN113651814A (zh) | Kras突变蛋白抑制剂 | |
JP2018162263A (ja) | 環状エーテルピラゾール−4−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 | |
TWI687423B (zh) | 雜環衍生物及其用途(二) | |
JP7166028B2 (ja) | 高活性stingタンパク質アゴニスト化合物 | |
CN104592211B (zh) | 联苯类化合物及其用途 | |
TWI716976B (zh) | 高活性sting蛋白激動劑 | |
JP2018522847A (ja) | 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類 | |
JP2023508097A (ja) | タンパク質分解剤化合物の製造方法及び使用 | |
EP4072679A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
KR20220115557A (ko) | 아마이드 유도체 및 그 제조방법과 의학적 응용 | |
AU2019311121B2 (en) | Fused ring derivative used as FGFR4 inhibitor | |
TWI826492B (zh) | 經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法 | |
CN105732659B (zh) | 硝基咪唑类化合物及其制备方法和在制药中的用途 | |
WO2021018173A1 (zh) | 腺苷受体拮抗剂 | |
CN111377854B (zh) | Cxcr4抑制剂及其应用 | |
TW201930268A (zh) | 吲哚胺2,3-雙加氧酶抑制劑以及它們在醫學上的應用 | |
CN111171020A (zh) | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 | |
CN106573927A (zh) | 氧杂环庚烷‑2‑基‑吡唑‑4‑基‑杂环基‑甲酰胺化合物和使用方法 | |
CN115557913A (zh) | 苯并氮杂环类化合物及其在药物中的应用 | |
JP7247144B2 (ja) | ジヒドロクロメン誘導体 | |
CA3014581A1 (en) | Cortistatin analogs | |
KR20230135541A (ko) | 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도 | |
WO2023215449A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |